SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.319
AS - Asia 7.992
EU - Europa 4.276
SA - Sud America 1.412
AF - Africa 193
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 9
Totale 28.216
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.032
SG - Singapore 3.358
CN - Cina 1.501
PL - Polonia 1.294
BR - Brasile 1.150
VN - Vietnam 847
IT - Italia 784
HK - Hong Kong 718
DE - Germania 388
TR - Turchia 361
BD - Bangladesh 356
GB - Regno Unito 341
UA - Ucraina 327
SE - Svezia 277
RU - Federazione Russa 215
FR - Francia 201
IN - India 153
JP - Giappone 148
ID - Indonesia 138
CA - Canada 126
AR - Argentina 108
MX - Messico 107
NL - Olanda 90
FI - Finlandia 86
ZA - Sudafrica 75
IQ - Iraq 67
IE - Irlanda 53
PK - Pakistan 44
AT - Austria 41
ES - Italia 37
JO - Giordania 35
EC - Ecuador 34
KR - Corea 32
VE - Venezuela 32
CO - Colombia 28
MA - Marocco 27
SA - Arabia Saudita 27
PH - Filippine 26
BE - Belgio 24
MY - Malesia 23
AE - Emirati Arabi Uniti 22
TN - Tunisia 22
CL - Cile 19
UZ - Uzbekistan 17
AU - Australia 14
RO - Romania 14
DZ - Algeria 13
CH - Svizzera 12
EG - Egitto 12
AL - Albania 11
AZ - Azerbaigian 11
ET - Etiopia 11
JM - Giamaica 11
NP - Nepal 11
IR - Iran 10
KE - Kenya 10
LT - Lituania 10
PE - Perù 10
PT - Portogallo 10
BO - Bolivia 9
PY - Paraguay 9
LB - Libano 8
OM - Oman 8
BG - Bulgaria 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
GE - Georgia 7
IL - Israele 7
KG - Kirghizistan 7
PS - Palestinian Territory 7
RS - Serbia 7
DO - Repubblica Dominicana 6
GR - Grecia 6
HN - Honduras 6
MD - Moldavia 6
SC - Seychelles 6
UY - Uruguay 6
XK - ???statistics.table.value.countryCode.XK??? 6
BH - Bahrain 5
KZ - Kazakistan 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AO - Angola 4
DK - Danimarca 4
KH - Cambogia 4
LV - Lettonia 4
NI - Nicaragua 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SV - El Salvador 4
BY - Bielorussia 3
CY - Cipro 3
GA - Gabon 3
GY - Guiana 3
HR - Croazia 3
QA - Qatar 3
SY - Repubblica araba siriana 3
BB - Barbados 2
EU - Europa 2
Totale 28.175
Salva come PNG Salva come JPEG
Città #
Singapore 1.943
Ashburn 1.643
Fairfield 1.499
Warsaw 1.289
Woodbridge 1.181
San Jose 980
Houston 768
Hong Kong 705
Santa Clara 617
Seattle 617
Chandler 551
Jacksonville 497
Wilmington 496
Cambridge 486
Beijing 393
Ann Arbor 380
Izmir 300
Ho Chi Minh City 282
Dallas 265
Los Angeles 217
Princeton 183
Hanoi 182
Nanjing 170
New York 167
Milan 164
Lauterbourg 154
Tokyo 144
São Paulo 113
Jakarta 109
The Dalles 109
San Diego 108
Boardman 104
Council Bluffs 99
Columbus 98
Dearborn 94
Dong Ket 82
London 75
Helsinki 74
Menlo Park 69
Mexico City 68
Moscow 68
Nanchang 68
Chicago 58
Ferrara 54
Bologna 51
Buffalo 47
Tianjin 47
Orem 46
Hebei 45
Rome 45
Falls Church 42
Shanghai 42
Toronto 41
Brooklyn 39
Rio de Janeiro 38
Shenyang 38
Mountain View 34
Atlanta 33
Phoenix 33
Da Nang 32
Haiphong 32
Munich 31
Nuremberg 31
San Francisco 31
Boston 30
Denver 30
Johannesburg 30
Baghdad 29
Montreal 27
Belo Horizonte 26
Changsha 26
Frankfurt am Main 26
Washington 26
Jiaxing 25
Redwood City 25
Stockholm 25
Kunming 24
Biên Hòa 22
Brussels 22
Manchester 22
Norwalk 22
Vienna 22
Brasília 20
Poplar 20
Chennai 19
Curitiba 19
Orange 19
Amsterdam 18
Dhaka 18
Hangzhou 17
Hải Dương 17
Naples 17
Porto Alegre 17
Scottsdale 16
Guangzhou 15
Jinan 15
Tashkent 15
Amman 14
Charlotte 14
Fuzhou 14
Totale 19.264
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 541
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 391
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 299
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 296
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 279
Development of sentinel node localization and ROLL in breast cancer in Europe 278
A novel radioguided surgery technique exploiting β- decays 277
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 277
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 269
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 254
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 247
Early use of abiraterone and radium-223 in metastatic prostate cancer 245
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 241
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 240
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 232
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 226
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 224
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 223
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 223
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 218
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 217
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 216
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 214
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 211
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 211
A parathyroid carcinoma within a cold thyroid nodule 209
Radioimmunotherapy in brain tumors 206
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 204
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 204
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 203
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 203
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 201
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 196
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 195
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 193
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 193
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 191
[18 f]f-psma-1007 radiolabelling without an on-site cyclotron: A quality issue 190
Yttrium-labelled peptides for therapy of NET 186
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 186
A delphic consensus assessment: Imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 186
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 184
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 184
177Lu specific activity influence over DOTATATE radiolabeling: experimental data 183
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 179
68ga-psma-11 pet/ct-guided stereotactic body radiation therapy retreatment in prostate cancer patients with psa failure after salvage radiotherapy 179
Neuroendocrine tumors 178
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 178
Positron emission tomography for the detection of colorectal adenomas 177
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 176
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 175
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 175
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 172
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 171
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 171
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 170
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 169
Financial aspects of sentinel lymph node biopsy in early breast cancer 169
Sentinel lymph node biopsy in pregnant patients with breast cancer 168
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 168
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 167
Dosimetry for treatment with radiolabelled somatostatin analogues. A review 167
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 166
Long-term results of PRRT in advanced bronchopulmonary carcinoid 166
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 166
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors 166
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 165
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 164
Yttrium-based therapy for neuroendocrine tumors 164
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 162
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 162
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 161
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 161
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 160
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 159
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 159
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 158
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 158
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting 158
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 157
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 157
Erratum: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 156
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 156
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 156
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 155
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 153
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 153
Quantitative accuracy of177Lu SPECT imaging for molecular radiotherapy 152
Exploratory Analysis of 18F-3’-deoxy-3’-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer 152
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 151
OXavidin for tissue targeting biotinylated therapeutics 150
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 150
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 149
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 149
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients 149
CAR-T cell therapy: A potential new strategy against prostate cancer 149
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review 149
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 147
PET/CT and breast cancer subtypes 147
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 147
Totale 19.294
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.849
Totale 149.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021258 0 0 0 0 0 0 0 0 0 0 0 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20254.132 58 97 333 157 510 407 151 253 697 608 646 215
2025/202610.884 862 523 1.044 1.089 1.532 610 1.343 599 1.031 1.181 651 419
Totale 28.760